Search clinical trials for: Escalating dose

Total 20870 results

Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

A Randomized, Double-blind,Dose-escalating, Single-dose, Oral Phase I Clinical Study of Flunotinib Healthy People

Healthy Person

China
University of Oxford
Bill and Melinda Gates Foundation; University Hospitals Bristol and Weston...

Recruiting

A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™

Malaria,Falciparum

United Kingdom
AvenCell Europe GmbH
Allucent (NL) BV

Recruiting

Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

Germany, Netherlands
CSL Behring

Recruiting

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Complement Deficiencies

Australia
National Heart, Lung, and Blood Institute (NHLBI)

Not yet recruiting

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Sickle Cell Disease | Sickle Cell Disorders | Hb-SS Disease | Hemoglobin S | Disease Sickle Cell Anemia | Hemoglobin Beta Thalassemia Disease

United States
CHU de Quebec-Universite Laval
Canadian Institutes of Health Research (CIHR)

Not yet recruiting

A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy (PRODIGY-1)

Cancer | Prostate Cancer | Metastatic Cancer | Metastatic Prostate Cancer
Biocad

Recruiting

Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL) (BLUEBELL)

Spinal Muscular Atrophy (SMA)

Belarus, Russian Federation
Protalix

Recruiting

A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels

Gout

New Zealand
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Escalating Doses of SIM0348 as a Single Agent in Advanced Solid Tumors

Advanced Solid Tumors
Children's Cancer Group, China
Xiangya Hospital of Central South University; Qilu Hospital of Shandong University and other collaborators

Recruiting

Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)

T-cell Lymphoblastic Lymphoma

China
Oasis Pharmaceuticals, LLC
Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases...

Recruiting

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis | Nonalcoholic Fatty Liver

United States
University of Zurich

Recruiting

Dose Escalation for SBRT of Recurrent VT Ventricular Tachyarrhythmia - a Single Center, Phase II Clinical Trial (DEFT STAR)

Ventricular Tachycardia

Switzerland
Ichnos Sciences SA

Recruiting

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, Australia
Kiora Pharmaceuticals, Inc.

Recruiting

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) (ABACUS)

Retinitis Pigmentosa | Choroideremia

Australia
Naval Medical Research Center
The 108 Military Central Hospital; Naval Medical Research Unit TWO (NAMRU-2); Australian Defence Force Malaria and Infectious Disease Institute (ADF MIDI) and other collaborators

Not yet recruiting

Escalating Monthly Doses of Tafenoquine in Healthy Volunteers (TQ)

Prophylaxis

Vietnam
University of Illinois at Chicago

Recruiting

Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) (VEN-OM)

Relapsed or Refractory Hematologic Malignancies

United States
AVEM HealthCare

Not yet recruiting

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 (ARDOXSO)

Covid19 | Acute Respiratory Distress Syndrome | Novel Coronavirus Pneumonia

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

Multiple Myeloma

Belgium, Korea, Republic of, Denmark, United Kingdom, Australia, New Zealand, Italy, Spain, France
AvenCell Europe GmbH
PHARMALOG Institut für klinische Forschung GmbH

Recruiting

Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Acute Myeloid Leukemia (AML)

Germany
Institut Paoli-Calmettes
INATHERYS

Recruiting

Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03)

Acute Lymphoblastic Leukemia, in Relapse | Acute Myeloid Leukemia, in Relapse | Mixed Phenotype Acute Leukemia | Acute Lymphoblastic Leukemia Recurrent | Acute Myeloid Leukaemia Recurrent

France
Loyola University
National Cancer Institute (NCI)

Recruiting

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Melanoma

United States
South Plains Oncology Consortium

Recruiting

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Recurrent or Refractory Solid Tumors

United States
Genentech, Inc.

Active, not recruiting

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Advanced/Metastatic Tumors

Spain, United States, Korea, Republic of, Australia, France, Japan, Canada
University of Sao Paulo
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaborators

Enrolling by invitation

Ibogaine in the Treatment of Alcoholism: a Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial

Alcoholism

Brazil
AvenCell Europe GmbH
PHARMALOG Institut für klinische Forschung GmbH

Terminated

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

Prostate Cancer

Germany
Noema Pharma AG

Completed

A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

Childhood-Onset Fluency Disorder

United States, Australia
Contineum Therapeutics

Completed

Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers

Multiple Sclerosis

United States
Pfizer

Completed

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus Type 2

United States
Biocad

Completed

Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers

Healthy

Russian Federation
Astellas Pharma Global Development, Inc.
Seagen Inc.

Completed

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Metastatic Urothelial Cancer and Other Malignant Solid Tumors

United States, Canada
Brii Biosciences Limited

Completed

A Study of BRII-297 in Healthy Adult Subjects

Postpartum Depression

Australia
Helen Reynolds
Desmond Tutu HIV Centre; Infectious Disease Institute, Kampala, Uganda

Active, not recruiting

Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin (DoRIS)

Tuberculosis | Hiv

Uganda, South Africa
Pfizer

Terminated

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Prostatic Neoplasms

United States
Huashan Hospital

Active, not recruiting

A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL (ORMD2021)

Primary Central Nervous System Lymphoma

China
Telavant, Inc.
Pfizer

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

Healthy

United States
Children's Hospital Los Angeles

Completed

A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin (VIT-B)

Refractory Solid Tumors in Children

United States
Children's National Research Institute
Foundation to Eradicate Duchenne

Active, not recruiting

Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States
M.D. Anderson Cancer Center

Completed

Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy

Lung Cancer

United States
National Institute of Allergy and Infectious Diseases...

Terminated

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

Gastroenteritis Escherichia Coli | Immunisation

Bangladesh
Haisco Pharmaceutical Group Co., Ltd.

Completed

Single Escalating Dose Study Of HSK7653 In Healthy Subjects

T2DM (Type 2 Diabetes Mellitus)

China
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Neuroblastoma

United States
Kira Pharmacenticals (US), LLC.

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of KP104

Paroxysmal Nocturnal Hemoglobinuria

Australia
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Melanoma (Skin)

United States
Hackensack Meridian Health
Millennium Pharmaceuticals, Inc.

Completed

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT (Thal/Mel/Vel)

Multiple Myeloma

United States
Shin Poong Pharmaceutical Co. Ltd.

Terminated

A Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356

Ischemic Stroke | Atherosclerosis

United Kingdom
AvenCell Europe GmbH
GCP-Service International Ltd. & Co. KG

Terminated

Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Relapsed AML | Refractory AML

Germany
PegBio Co., Ltd.
Covance

Completed

A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study

Healthy Subjects

United States
Michael Hoelscher
Radboud University Medical Center; German Federal Ministry of Education and... and other collaborators

Completed

BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

Pulmonary Tuberculoses | Other Specified Pulmonary Tuberculosis

South Africa
AGC Biologics S.p.A.

Completed

A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors

Advanced Solid Tumors

Italy

3

Subscribe